Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00095-5/abstract?utm_campaign=update-langas&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_langas&_hsenc=p2ANqtz-_g4Kujee_bo8uKO9HzUF50ycywM4IGydhRu_eSRwJ3u--5amK4aVrnAh-8ahKa6KIPz_3eXBbAHYIbCc9xQbEKYyjEBw&_hsmi=315988147&utm_content=315489009&utm_source=hs_email